查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088683

僵直性脊椎炎市場：2026-2032年全球市場預測（依治療方法、給藥途徑、患者年齡層、疾病分類及最終用戶分類）

Ankylosing Spondylitis Market by Therapy Type, Administration Route, Patient Age Group, Disease Classification, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，僵直性脊椎炎市場規模將達到 99.8 億美元，複合年成長率為 6.85%。

主要市場統計數據
基準年 2025 62.7億美元
預計年份：2026年 66.8億美元
預測年份 2032 99.8億美元
複合年成長率 (%) 6.85%

僵直性脊椎炎是中軸型脊椎頻譜這一大類疾病中的一種，後者是一種慢性免疫介導的發炎性疾病，主要涉及骶髂關節和脊椎。該市場的發展受到早期診斷、生物製藥和標靶合成療法的廣泛應用，以及對長期管理發炎性腰痛、僵硬、疲勞、運動功能下降、疾病進展和關節外症狀（如急性前葡萄膜炎、乾癬和發炎性腸道疾病）的需求不斷成長的影響。

檢驗的臨床文獻一致表明，中軸型脊椎關節炎影響著全球一定比例的成年人口，其盛行率因地區、HLA-B27頻率、診斷可及性和病例定義而異。成長機會主要集中在MRI輔助診斷、風濕病轉診途徑、TNF抑制劑、IL-17抑制劑、JAK抑制劑、生物相似藥、病患支持計畫、達標治療、實證數位化監測等方面。

僵直性脊椎炎領域的變革性變化

僵直性脊椎炎的治療模式正在轉變，從基於影像學檢查結果的晚期診斷轉向早期發現伴隨發炎性腰痛或非影像學觀察的中軸型脊椎關節炎。 ASAS 分類概念的採用、骶髂關節 MRI 檢查、臨床適用時的 HLA-B27 檢測、C 反應蛋白測定以及 BASDAI 和 ASDAS 等標準化疾病活動度評估工具的引入，正在改變臨床醫生在影像學檢查確診結構性損傷之前對患者的評估方式。

人工智慧對僵直性脊椎炎治療的累積影響

人工智慧（AI）並非取代臨床判斷，而是在僵直性脊椎炎的整個臨床診療過程中不斷提升其影響力。目前正在評估人工智慧驅動的影像工具，以提高骶髂關節炎檢測的準確性，量化MRI上的發炎和結構性病變，輔助X光片評分，並減少解讀差異，這在肌肉骨骼放射學專業知識有限的地區尤其重要。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

由於完善的風濕病學網路、生物製藥的僵直性脊椎炎應用、基於指南的治療、積極的臨床研究以及強大的真實世界證據基礎設施，北美和歐洲仍然是強直性脊椎炎的重要市場。美國、加拿大、英國、英國、法國、義大利和西班牙對先進療法的需求持續旺盛，而歐洲則受益於生物類似藥的引入、藥物安全監測系統、集中式或國家級醫療技術評估流程以及結構化的報銷途徑。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協地區，由於醫院基礎設施的改善、私人醫療網路的擴張以及風濕病診療服務的普及，僵直性脊椎炎的診斷水準正在逐步提高；然而，成本效益、專科醫生密度和報銷制度的穩定性仍然是阻礙因素。在海灣合作理事會（GCC）國家，高額的醫療支出、生物製藥的普及、國家醫療改革計劃以及對數位醫療平台的投資，推動了專科醫療的發展。尤其是在都市區三級醫療機構，越來越多的複雜免疫介導疾病透過專科途徑進行管理。

主要國家僵直性脊椎炎的趨勢

美國在品牌生物製藥和標靶治療的應用方面主導，這得益於專科醫生的診療、保險公司主導的處方藥清單管理、患者支持項目以及積極的臨床研究。另一方面，加拿大則強調基於實證醫學的保險報銷、省級准入決定以及公平的醫療服務。在墨西哥和巴西，對生物製藥和生物相似藥的需求不斷成長，但保險覆蓋範圍、公共醫療系統能力以及經濟負擔方面的差異正在影響其應用。在歐洲，英國、德國、法國、義大利和西班牙依靠國家醫療體系、臨床指南、衛生技術評估以及以生物相似藥主導的成本管理。同時，在俄羅斯，需求依然強勁，但在准入、報銷和供應鏈方面面臨著許多複雜問題。

為行業領導者提供的實用建議

行業領導者應優先考慮早期診斷項目、風濕症醫師培訓以及轉診工具，以幫助區分發炎性和機械性腰痛。與影像中心、基層醫療網路、整形外科、眼科、胃腸科、皮膚科以及病患權益組織合作，可以減少診斷延誤，有助於識別關節外病變，並加速治療啟動。

調查方法

本執行摘要基於對來自同行評審的風濕病學文獻、法規核准、臨床實踐指南、衛生技術檢驗趨勢、流行病學出版物、保險公司政策趨勢以及權威衛生機構資訊的三角分析。該分析優先考慮來自風濕病學會、監管機構、臨床試驗註冊庫、藥物安全監測資訊來源、流行病學綜述以及已發表的真實世界研究的檢驗證據。

結論

僵直性脊椎炎市場正朝著更早期的診斷、更個人化的治療方案以及保險公司和醫療系統更嚴格的證據要求方向發展。生物製藥、生物相似藥、標靶合成療法、影像學創新、結構化的疾病活動度測量以及人工智慧驅動的護理協調正在重新定義相關人員應對慢性發炎、功能障礙和長期疾病負擔的方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：僵直性脊椎炎市場：依治療類型分類

  • 藥理學
    • NSAIDs
    • 生物製劑
    • DMARDs
  • 非藥物療法
    • 物理治療
    • 姿勢訓練
  • 手術治療
    • 全髖關節置換術
    • 脊椎截骨術

第8章：僵直性脊椎炎市場：依給藥途徑分類

  • 注射藥物
    • 靜脈注射
    • 皮下注射
  • 靜脈
  • 口服
    • 膠囊
    • 藥片

第9章：僵直性脊椎炎市場：依患者年齡層別分類

  • 成人
  • 老年人
  • 兒童

第10章僵直性脊椎炎市場：依疾病分類

  • 中軸型脊椎關節炎（axSpA）
  • 周邊型脊椎關節炎

第11章僵直性脊椎炎市場：依最終用戶分類

  • 居家照護中心
  • 醫院
  • 專科診所

第12章僵直性脊椎炎市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章僵直性脊椎炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章僵直性脊椎炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Biothera Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celltrion Healthcare Co.,Ltd.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Drugs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Trinity Biotech PLC
  • UCB, Inc.
  • Xian Janssen Pharmaceutical Ltd
Product Code: MRR-A339DAEFAA9A

The Ankylosing Spondylitis Market is projected to grow by USD 9.98 billion at a CAGR of 6.85% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.27 billion
Estimated Year [2026] USD 6.68 billion
Forecast Year [2032] USD 9.98 billion
CAGR (%) 6.85%

Ankylosing spondylitis, commonly discussed within the broader axial spondyloarthritis spectrum, is a chronic immune-mediated inflammatory disease that primarily affects the sacroiliac joints and spine. The market is shaped by earlier diagnosis, wider use of biologic and targeted synthetic therapies, and rising demand for long-term control of inflammatory back pain, stiffness, fatigue, mobility loss, structural progression, and extra-articular manifestations such as acute anterior uveitis, psoriasis, and inflammatory bowel disease.

Verified clinical literature consistently shows that axial spondyloarthritis affects a measurable share of the adult population globally, with prevalence varying by geography, HLA-B27 frequency, diagnostic access, and case definition. Growth opportunities are concentrated in MRI-enabled diagnosis, rheumatology referral pathways, TNF inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars, patient support programs, treat-to-target care, and evidence-based digital monitoring.

Transformative Shifts in the Ankylosing Spondylitis Landscape

The ankylosing spondylitis landscape is shifting from late-stage radiographic recognition toward earlier identification of inflammatory back pain and non-radiographic axial spondyloarthritis. Adoption of ASAS classification concepts, MRI of sacroiliac joints, HLA-B27 testing where clinically appropriate, C-reactive protein assessment, and standardized disease activity tools such as BASDAI and ASDAS is changing how clinicians evaluate patients before structural damage becomes visible on X-ray.

Treatment pathways are also transforming. NSAIDs remain foundational for symptom control, exercise and physiotherapy remain core non-pharmacologic interventions, and biologics and targeted synthetic DMARDs are increasingly used for patients with persistently active disease. Biosimilar competition is improving affordability in many markets, and payers are requiring clearer evidence of response, persistence, safety, functional improvement, and quality-of-life gains.

Cumulative Impact of Artificial Intelligence in Ankylosing Spondylitis Care

Artificial intelligence is accumulating influence across the ankylosing spondylitis care pathway rather than replacing clinical judgment. AI-supported imaging tools are being evaluated to improve detection of sacroiliitis, quantify inflammatory and structural lesions on MRI, support radiographic scoring, and reduce variability in interpretation, which is especially important where musculoskeletal radiology expertise is limited.

AI also supports risk stratification, real-world evidence generation, patient-reported outcome analysis, and treatment adherence monitoring. When integrated with electronic health records, claims data, laboratory markers, imaging repositories, and wearable mobility signals, AI can help identify delayed referrals, predict flare patterns, support pharmacovigilance, and guide value-based decisions while maintaining clinician oversight, data privacy, algorithm transparency, and regulatory compliance.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America and Europe remain highly influential ankylosing spondylitis markets due to established rheumatology networks, broad biologic access, guideline-driven treatment, active clinical research, and strong real-world evidence infrastructure. The United States, Canada, the United Kingdom, Germany, France, Italy, and Spain show continued demand for advanced therapies, while Europe benefits from biosimilar adoption, pharmacovigilance systems, centralized or national health technology assessment processes, and structured reimbursement pathways.

Asia-Pacific is expanding through rising diagnosis in China, Japan, India, South Korea, and Australia, supported by larger patient pools, improving specialty care, growing MRI availability, and increasing awareness of inflammatory back pain. Latin America shows opportunity in Brazil and Mexico but faces uneven reimbursement, public-private access gaps, and diagnostic delays. The Middle East, led by Gulf health systems, is investing in tertiary specialty care, digital health infrastructure, and access to advanced therapies, while Africa remains constrained by limited rheumatology workforce, delayed diagnosis, restricted imaging availability, and affordability barriers.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Across ASEAN, improving hospital infrastructure, expanding private healthcare networks, and broader access to rheumatology are gradually strengthening ankylosing spondylitis diagnosis, although affordability, specialist density, and reimbursement consistency remain limiting factors. The GCC is advancing specialty care through high health expenditure, biologic availability, national health transformation programs, and investment in digital health platforms, particularly in urban tertiary centers where complex immune-mediated diseases are increasingly managed through specialist pathways.

The European Union remains a benchmark for guideline adoption, pharmacovigilance, cross-border regulatory consistency, health technology assessment, and biosimilar integration. BRICS markets combine large patient potential with varied reimbursement maturity, local manufacturing priorities, and uneven access to MRI and biologics, making access strategy country-specific. G7 markets lead in innovation uptake, clinical evidence generation, real-world data use, and payer scrutiny, while NATO-aligned countries often overlap with advanced procurement systems, regulatory harmonization, resilient medicine supply-chain priorities, and established standards for biologic and biosimilar governance.

Key Country Insights for Ankylosing Spondylitis

The United States leads in branded biologic and targeted therapy uptake, supported by specialist care, insurance-driven formulary management, patient assistance programs, and active clinical research, while Canada emphasizes evidence-based reimbursement, provincial access decisions, and equitable care delivery. Mexico and Brazil show growing need for biologics and biosimilars, but coverage variability, public system capacity, and affordability shape adoption. In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on national health systems, clinical guidelines, health technology assessment, and biosimilar-driven cost management; Russia maintains demand but faces access, reimbursement, and supply-chain complexities.

China and India represent high-volume opportunities as diagnosis improves, rheumatology capacity expands, and biosimilar availability increases, although affordability and regional care gaps persist. Japan, South Korea, and Australia benefit from mature specialty systems, structured reimbursement, established rheumatology practice standards, and consistent use of evidence-based treatment algorithms. Across these countries, the most important differentiators are early referral from primary care, access to MRI, payer acceptance of advanced therapies, treatment persistence, and long-term monitoring of safety and functional outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize early diagnosis programs, rheumatologist education, and referral tools that help distinguish inflammatory back pain from mechanical back pain. Partnerships with imaging centers, primary care networks, orthopedics, ophthalmology, gastroenterology, dermatology, and patient advocacy groups can reduce diagnostic delay, support recognition of extra-articular disease, and improve treatment initiation.

Commercial strategies should align biologic, biosimilar, and JAK inhibitor positioning with payer evidence needs, including sustained response, safety, adherence, functional improvement, work productivity, and quality-of-life outcomes. Organizations should invest in real-world evidence, AI-enabled patient identification, digital monitoring, pharmacovigilance, and market-specific access models that address reimbursement, affordability, treatment continuity, and responsible use of advanced therapies.

Research Methodology

This executive summary is based on triangulation of peer-reviewed rheumatology literature, regulatory approvals, clinical practice guidelines, health technology assessment patterns, epidemiology publications, payer policy trends, and publicly available information from recognized health authorities. The analysis prioritizes validated evidence from rheumatology associations, regulatory agencies, clinical trial registries, pharmacovigilance sources, epidemiological reviews, and published real-world studies.

The methodology combines qualitative assessment of treatment pathways with market-facing evaluation of access, reimbursement, regional infrastructure, competitive intensity, biosimilar adoption, diagnostic capability, and technology adoption. Insights are presented conservatively, avoiding unverified forecasts and emphasizing data-backed trends relevant to strategic planning in ankylosing spondylitis and axial spondyloarthritis.

Conclusion

The ankylosing spondylitis market is moving toward earlier diagnosis, more personalized therapy selection, and stronger evidence requirements from payers and health systems. Biologics, biosimilars, targeted synthetic therapies, imaging innovation, structured disease activity measurement, and AI-supported care coordination are redefining how stakeholders address chronic inflammation, functional limitation, and long-term disease burden.

Future market leadership will depend on balancing innovation with access. Organizations that combine clinical credibility, real-world evidence, patient-centered support, responsible digital integration, and region-specific affordability strategies will be best positioned to improve outcomes and capture sustainable growth in the evolving axial spondyloarthritis ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Ankylosing Spondylitis Market, by Therapy Type

  • 7.1. Pharmacological
    • 7.1.1. NSAIDs
    • 7.1.2. Biologics
    • 7.1.3. DMARDs
  • 7.2. Non-Pharmacological
    • 7.2.1. Physiotherapy
    • 7.2.2. Postural Training
  • 7.3. Surgical
    • 7.3.1. Hip Replacement
    • 7.3.2. Spinal Osteotomy

8. Ankylosing Spondylitis Market, by Administration Route

  • 8.1. Injectable
    • 8.1.1. Intravenous Infusion
    • 8.1.2. Subcutaneous Injection
  • 8.2. Intravenous
  • 8.3. Oral
    • 8.3.1. Capsules
    • 8.3.2. Tablets

9. Ankylosing Spondylitis Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Ankylosing Spondylitis Market, by Disease Classification

  • 10.1. Axial Spondyloarthritis (axSpA)
  • 10.2. Peripheral Spondyloarthritis

11. Ankylosing Spondylitis Market, by End User

  • 11.1. Homecare Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Ankylosing Spondylitis Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Ankylosing Spondylitis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Ankylosing Spondylitis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. Biothera Pharmaceuticals, Inc.
  • 16.4. Boehringer Ingelheim International GmbH
  • 16.5. Bristol-Myers Squibb Company
  • 16.6. Celgene Corporation
  • 16.7. Celltrion Healthcare Co.,Ltd.
  • 16.8. Eisai Co., Ltd
  • 16.9. Eli Lilly and Company
  • 16.10. Gilead Sciences, Inc.
  • 16.11. GlaxoSmithKline PLC
  • 16.12. Hetero Drugs Limited
  • 16.13. Johnson & Johnson Services Inc.
  • 16.14. Merck & Co. Inc.
  • 16.15. Mylab Discovery Solutions Pvt. Ltd.
  • 16.16. Novartis AG
  • 16.17. Pfizer, Inc.
  • 16.18. Reliance Life Sciences
  • 16.19. Samsung Bioepis Co., Ltd.
  • 16.20. Sandoz International GmbH
  • 16.21. Shanghai Pharmaceuticals Holding Co., Ltd.
  • 16.22. Takeda Pharmaceutical Company Limited
  • 16.23. Trinity Biotech PLC
  • 16.24. UCB, Inc.
  • 16.25. Xian Janssen Pharmaceutical Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NSAIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NSAIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DMARDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DMARDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DMARDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POSTURAL TRAINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POSTURAL TRAINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POSTURAL TRAINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SURGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SURGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SURGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIP REPLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIP REPLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIP REPLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SPINAL OSTEOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SPINAL OSTEOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SPINAL OSTEOTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERIPHERAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PERIPHERAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERIPHERAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOMECARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOMECARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOMECARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 254. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 255. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 256. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 286. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 287. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 288. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 289. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 297. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 308. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 309. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 310. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 341. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 342. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 343. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 352. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 353. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 354. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 355. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE,